Compare Freshworks Inc (FRSH) vs Oruka Therapeutics Inc. Common Stock (ORKA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Freshworks Inc vs Oruka Therapeutics Inc. Common Stock — how do they compare? Freshworks Inc trades at $13.69 (market cap $3.62B), while Oruka Therapeutics Inc. Common Stock trades at $75.2 (market cap $5.18B). The key difference: Oruka Therapeutics Inc. Common Stock is the larger of the two by market cap, and Freshworks Inc is trading nearer its 52-week high, Oruka Therapeutics Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Freshworks Inc for 40 Days and Oruka Therapeutics Inc. Common Stock for 0 Days on average.
| FRSH | ORKA | |
|---|---|---|
Market Cap | $3.62B | $5.18B |
Volume | 4,303,742 | 490,798 |
Sector | Technology | Health |
52-Week High | $13.92 | $113.08 |
52-Week Low | $6.88 | $26.19 |
Typical Hold Time | 40 Days | 0 Days |
Enterprise Value | $2.99B | $4.31B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Freshworks (FRSH) trades at $13.69, down 1.65% on the day, with a bullish technical signal and strong fundamental momentum. The company achieved GAAP profitability in Q2 2026, with revenue growth of 16% year-over-year and a net income margin of 20.49%. Analyst consensus is split evenly between Buy and Hold, with a price target of $14.60, suggesting modest upside from current levels. Recent news highlights AI adoption and enterprise growth as key drivers.
The outlook for FRSH is positive, supported by sustained revenue growth, improving profitability, and strategic focus on AI and employee experience products. Risks include competitive pressures in the SaaS sector and execution challenges in maintaining growth momentum. The stock presents an opportunity for investors seeking exposure to a profitable, growing software company with a reasonable valuation.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Freshworks Inc
Freshworks Inc provides software as a service platform that enables small and medium-sized businesses to support customers through e-mail, phone, website, and social networks. It offers solutions that serve the needs of users in the CX and ITSM categories, and have also expanded its offering with Sales and Marketing automation products. These product offerings enable organizations to acquire, engage, and better serve their customers and employees.
Read more on FRSH →About Oruka Therapeutics Inc. Common Stock
Oruka Therapeutics, Inc. is a clinical-stage biotechnology company developing extended half-life monoclonal antibodies for plaque psoriasis, psoriatic arthritis, and related dermatologic conditions, with lead candidates ORKA-001 and ORKA-002 in clinical trials.
Read more on ORKA →
